Literature DB >> 29576279

Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.

Nikolaos Benetatos1, James Hodson2, Ravi Marudanayagam1, Robert P Sutcliffe1, John R Isaac1, John Ayuk3, Tahir Shah4, Keith J Roberts5.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) display wide heterogeneity with highly variable prognosis. This study aimed to identify variables related to survival after surgical resection of PNET.
METHODS: A total of 143 patients were identified from a prospectively maintained database. Patient characteristics were analyzed and prognostic factors for overall survival and progression-free survival were evaluated. The WHO, ENETS and AJCC scoring systems were applied to the cohort, and their ability to predict patient outcomes were compared.
RESULTS: Multivariate analysis found that female gender, lymph node metastases and increasing WHO 2010 grade to be independently associated with reduced overall survival (P < 0.05). Patients requiring multi-visceral resection or debulking surgery found to be associated with shortest survival. ROC analysis found the ENETS and AJCC scoring systems to be similarly predictive of 5-year overall survival. Modified Ki67 significantly improved its accuracy in predicting 5-year overall survival (AUROC: 0.699 vs 0.605; P < 0.01).
CONCLUSIONS: Multi-visceral or debulking surgery is associated with poor outcomes. There seems to be no significant difference between enucleation and anatomical segmental resection. Available scoring systems have reasonable accuracy in stratifying disease severity, with no system identified as being superior. Prognostic stratification with modified grading systems needs further validation before applied in clinical practice.
Copyright © 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Pancreatic neuroendocrine tumors; Prognostic factors; Validation of staging systems

Mesh:

Substances:

Year:  2018        PMID: 29576279     DOI: 10.1016/j.hbpd.2018.03.002

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  8 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.

Authors:  Sara Krogh; Henning Grønbæk; Anders Riegels Knudsen; Peter Kissmeyer-Nielsen; Nynne Emilie Hummelshøj; Gitte Dam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

4.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

5.  Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients.

Authors:  Noémie S Minczeles; Casper H J van Eijck; Marjon J van Gils; Marie-Louise F van Velthuysen; Els J M Nieveen van Dijkum; Richard A Feelders; Wouter W de Herder; Tessa Brabander; Johannes Hofland
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-01       Impact factor: 10.057

6.  Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, China.

Authors:  Mengfei Fu; Li Yu; Liu Yang; Yang Chen; Xiao Chen; Qinyu Hu; Hui Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

7.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08

8.  A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms.

Authors:  Min Yang; Lin Zeng; Wen-Qing Yao; Neng-Wen Ke; Chun-Lu Tan; Bo-le Tian; Xu-Bao Liu; Bo Xiang; Yi Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.